Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thromboembolism 7Venous Thrombosis 5Pulmonary Embolism 4Neoplasms 4Thromboembolism 2Lung Neoplasms 2Thrombosis 1Thrombocytopenia 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1Hemorrhage 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × Tinzaparin × Clear all
NCT04731558 2025-02-14

PREPOSTEROUS

Helsinki University Central Hospital

Phase 4 Recruiting
1,012 enrolled
Gastrointestinal

Hemorrhage, Liver Neoplasms, Pulmonary Embolism, Venous Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡